What Is Rhino Tranq? Medetomidine, Fentanyl and the Shift Away From Xylazine

The illicit fentanyl supply is changing again.

For several years, public health officials have warned about xylazine, commonly called “tranq,” appearing alongside fentanyl. Now another powerful veterinary sedative is becoming increasingly important: medetomidine, sometimes called “rhino tranq,” “mede,” or “dex.”

Medetomidine has already been identified in the illicit fentanyl supply in several Kentucky counties, making this an emerging concern for people who use opioids and their families across the Commonwealth.

Unlike fentanyl, medetomidine is not an opioid. It can cause profound sedation, dangerously slow heart rate and low blood pressure. Repeated exposure may also lead to a potentially severe withdrawal syndrome.

Another concern is that people may never knowingly choose to use medetomidine. It can be mixed into illicit fentanyl, meaning someone may be exposed without realizing it.

Understanding what rhino tranq is, how it differs from xylazine, what happens during an overdose and when medical help may be necessary is becoming increasingly important as the illicit opioid supply continues to change.

What Is Rhino Tranq?

“Rhino tranq” is an emerging name for medetomidine, a powerful alpha-2 adrenergic agonist used as a veterinary sedative.

The Centers for Disease Control and Prevention (CDC) reports that medetomidine is not approved for use in people and is increasingly being detected in the illegal drug supply, primarily alongside illegally manufactured fentanyl.

Names associated with medetomidine may include rhino tranq, mede and dex.

Medetomidine should not be confused with xylazine. Although both are non-opioid veterinary sedatives that have appeared in fentanyl, they are different drugs with different emerging patterns of intoxication and withdrawal.

In April 2026, the CDC issued a national health advisory warning about increasing medetomidine detections and the potential for overdose complications and severe withdrawal.

Federal data illustrate how quickly the substance has emerged. Law-enforcement reports involving medetomidine increased from 247 in 2023 to 2,616 in 2024 and 8,233 in 2025.

Why Is Medetomidine Showing Up in Fentanyl?

Most people exposed to medetomidine are not necessarily seeking it.

Instead, medetomidine is increasingly being detected as part of the illicit opioid supply, particularly in samples containing fentanyl.

That creates an important risk: someone purchasing fentanyl may have no reliable way of knowing what else is in it.

The contents of illicit drugs can change between communities, dealers and even individual batches. A product sold as fentanyl may contain medetomidine, xylazine or other substances in addition to the opioid itself.

CDC-supported surveillance during the second half of 2025 detected medetomidine in opioid-positive samples across multiple regions of the country. Among participating sentinel sites, approximately 74% of opioid-positive samples in the Northeast contained medetomidine, compared with 56% in the Midwest and 30% in the South.

Those surveillance sites do not represent every local drug market, but they show that medetomidine is no longer an isolated regional finding.

Rhino Tranq Has Been Detected in Kentucky

This emerging drug trend has direct relevance to Kentucky.

Public health information from the University of Kentucky reports that medetomidine has been identified in the illicit fentanyl supply in several Kentucky counties.

That does not mean every fentanyl sample in Kentucky contains medetomidine. Local drug supplies can differ substantially and change quickly.

It does mean that people using illicit opioids in Kentucky may encounter a substance they did not intend to take.

For someone already dependent on fentanyl, that uncertainty can affect more than overdose risk. Repeated, unrecognized exposure to medetomidine may also complicate withdrawal when that person attempts to stop using opioids.

If fentanyl use has become difficult to stop, Kentucky Recovery Center can help assess the pattern of substance use, withdrawal history, previous overdoses and other factors that may affect the appropriate level of treatment.

Medetomidine vs. Xylazine vs. Fentanyl

The terms surrounding the illicit opioid supply can become confusing, particularly as new substances emerge.

The simplest distinction is that fentanyl is an opioid, while medetomidine and xylazine are not.

	Medetomidine / Rhino Tranq	Xylazine / Tranq	Fentanyl
Drug type	Alpha-2 agonist sedative	Alpha-2 agonist sedative	Synthetic opioid
Opioid?	No	No	Yes
Naloxone directly reverses it?	No	No	Yes
Can appear in illicit fentanyl?	Yes	Yes	N/A
Major concerns	Profound sedation, slow heart rate, low blood pressure, severe withdrawal	Sedation, wounds and cardiovascular effects	Respiratory depression and fatal overdose

These differences help explain why an overdose involving today’s illicit fentanyl supply may not respond exactly as someone expects after naloxone is administered.

Is Medetomidine Replacing Xylazine?

Not everywhere.

One of the most significant shifts has been documented in Philadelphia, where CDC researchers found that medetomidine replaced xylazine as the most common adulterant in the city’s illicit opioid supply during the final four months of 2024.

That finding does not establish that medetomidine is replacing xylazine throughout Kentucky or the United States.

Instead, it shows how quickly local illicit drug supplies can change.

Xylazine remains an important public health concern, and some samples may contain medetomidine, xylazine and fentanyl together. The emerging problem is therefore bigger than a simple transition from one adulterant to another.

What Does “Dex” Mean in Street Drugs?

“Dex” is one of the terms federal health officials have associated with medetomidine.

The nickname may relate to dexmedetomidine, one of medetomidine’s two isomers. Dexmedetomidine itself has legitimate medical applications when administered under professional supervision.

Street terminology, however, is inconsistent.

Hearing terms such as “dex,” “mede” or “rhino tranq” does not reliably establish what a substance actually contains. Drug names can vary by location and change rapidly as the illicit market evolves.

What Does Rhino Tranq Do to the Body?

Medetomidine affects both the central nervous system and cardiovascular system.

According to the CDC, exposure may cause profound and sometimes prolonged sedation, significantly slowed heart rate and low blood pressure.

Potential effects include:

• Extreme drowsiness or sedation
• Reduced responsiveness
• Bradycardia, or an abnormally slow heart rate
• Hypotension, or dangerously low blood pressure
• Complicated overdose symptoms
• Severe withdrawal following repeated exposure

These effects become particularly concerning when medetomidine is combined with fentanyl.

Fentanyl can suppress breathing and cause fatal opioid overdose. Medetomidine can simultaneously contribute profound sedation and cardiovascular instability.

Does Narcan Work on Rhino Tranq?

Naloxone, commonly known by the brand name Narcan, does not directly reverse medetomidine.

Medetomidine is not an opioid, so naloxone cannot block its effects.

However, naloxone should still be administered whenever an opioid overdose is suspected.

Medetomidine is frequently detected with fentanyl. Naloxone can reverse the fentanyl component of an overdose even though sedation or cardiovascular effects caused by medetomidine may continue.

This explains why someone may remain extremely sleepy or unresponsive after receiving naloxone.

Persistent sedation does not necessarily mean the naloxone failed. Another substance may still be affecting the person’s body.

If someone is unresponsive or experiencing a suspected overdose, administer naloxone if available and call 911 immediately.

What Does Medetomidine Withdrawal Look Like?

Withdrawal is one of the most important differences families and treatment providers need to understand.

Repeated exposure to medetomidine may cause physical dependence, even when someone did not know the drug was present in the fentanyl they were using.

The CDC has identified symptoms that may include:

• Rapid heart rate
• Severe hypertension
• Tremors
• Changes in alertness
• Chest pain
• Severe nausea and vomiting

These symptoms can reflect significant disruption of the body’s autonomic nervous system, which regulates functions such as blood pressure and heart rate.

In severe cases, hospitalization or intensive medical treatment may be necessary.

Why Medetomidine Can Complicate Fentanyl Withdrawal

Someone who regularly uses illicit fentanyl may believe they know what withdrawal will feel like based on previous attempts to stop.

Medetomidine makes that assumption less reliable.

Between September 2024 and January 2025, clinicians at three Philadelphia health systems identified 165 hospitalized patients experiencing fentanyl withdrawal complicated by symptoms consistent with medetomidine withdrawal.

Some patients experienced severe hypertension and rapid heart rate, and researchers reported that the syndrome did not respond as expected to medications previously used for fentanyl and xylazine withdrawal.

This has an important implication for people seeking recovery:

Withdrawal from today’s illicit fentanyl supply may involve more than fentanyl.

A person may have repeatedly consumed medetomidine, xylazine or other substances without knowing it.

For that reason, unusually severe or unexpected withdrawal symptoms should be medically evaluated rather than assumed to be routine opioid withdrawal.

When Fentanyl Withdrawal May Require Medical Attention

Fear of withdrawal is one reason people sometimes delay seeking treatment.

The changing fentanyl supply makes professional assessment especially valuable because treatment providers can consider the person’s actual symptoms and history rather than assuming only one substance is involved.

Seek urgent medical attention for symptoms such as:

• Chest pain
• Extreme changes in heart rate
• Severe hypertension
• Loss of consciousness
• Breathing problems
• Seizures
• Persistent vomiting
• Significant changes in alertness

Someone experiencing these symptoms should not attempt to manage them solely through an addiction-treatment website or general online advice.

Emergency symptoms require emergency medical care.

Rhino Tranq Is Part of a Larger Polysubstance Problem

Medetomidine illustrates why the concept of addiction involving a single drug increasingly fails to describe today’s illicit opioid market.

Someone may intentionally use fentanyl while unknowingly consuming medetomidine. Another batch could contain xylazine. Other substances may also be present.

As a result, one product may expose a person to several pharmacologically different substances at once.

That can complicate:

• Overdose response
• Withdrawal
• Detoxification
• Medication decisions
• Treatment planning
• Relapse prevention

Effective treatment therefore needs to evaluate the whole pattern of substance use, rather than focusing only on the drug someone believes they have been taking.

What to Do During a Suspected Fentanyl or Rhino Tranq Overdose

Treat a suspected overdose involving fentanyl, medetomidine or an unknown drug combination as a medical emergency.

Call 911 and administer naloxone if available.

Follow instructions from emergency dispatchers, monitor breathing and responsiveness, and provide rescue breathing or CPR if trained and instructed to do so.

Stay with the person until emergency medical professionals arrive.

Do not assume someone is safe simply because naloxone has been given. If medetomidine or another non-opioid sedative is present, significant sedation and other symptoms may continue after the fentanyl component has been reversed.

When Fentanyl Use Becomes Difficult to Stop

For someone physically dependent on fentanyl, knowing that the drug supply is unpredictable does not necessarily make stopping easy.

Dependence can create withdrawal symptoms, intense cravings and repeated cycles of stopping and returning to use. Mental health conditions, trauma, stress, environment and other substance use can make that cycle even harder to interrupt.

The emergence of medetomidine adds another concern because someone may be physically exposed to substances they never intentionally chose to use.

Treatment can provide a structured path away from that uncertainty.

Rather than asking only, “What drug is this person using?” an effective assessment considers:

• How frequently opioids are being used
• Previous withdrawal experiences
• History of overdose
• Other substances being used
• Physical and mental health
• Previous treatment
• Current safety concerns
• Support at home
• Risk of returning to use

Those factors help determine whether someone needs medical stabilization, residential treatment or another appropriate level of care.

Opioid Addiction Treatment at Kentucky Recovery Center

Kentucky Recovery Center provides addiction treatment for adults struggling with opioids, fentanyl and polysubstance use.

Treatment begins with an individualized assessment so the clinical team can better understand substance use, mental health concerns, previous treatment experiences and recovery needs.

Care can then focus on the factors that contribute to continued substance use through evidence-based therapy, relapse-prevention work, recovery education and support for co-occurring mental health concerns when appropriate.

If someone’s symptoms indicate that medical detoxification or another level of medical care is necessary before beginning treatment, appropriate placement should be determined through clinical evaluation.

The goal is not simply to identify whether fentanyl contained medetomidine.

It is to help the person stop relying on an unpredictable illicit drug supply and build the skills and support necessary for long-term recovery.

Why Seeking Treatment Matters as the Fentanyl Supply Changes

The emergence of rhino tranq changes the risk calculation surrounding continued fentanyl use.

A person may tolerate one batch and encounter a completely different combination the next time. Previous experience cannot reliably predict the potency or ingredients of future illicit fentanyl.

That uncertainty is one reason treatment should not be postponed until someone knows exactly what substances they have been exposed to.

If fentanyl or opioid use is becoming difficult to control, Kentucky Recovery Center can help you or your loved one understand available treatment options, insurance coverage and the next appropriate step.

Reaching out does not require someone to already know what level of care they need. An admissions conversation can help clarify those options.

Frequently Asked Questions About Rhino Tranq

What is rhino tranq?

Rhino tranq is an emerging term for medetomidine, a powerful veterinary sedative increasingly detected in the U.S. illicit fentanyl supply. Other reported names include “mede” and “dex.”

Is medetomidine the same as xylazine?

No. Medetomidine and xylazine are different non-opioid sedatives. Both have been found with fentanyl, but their effects and emerging withdrawal patterns are not identical.

Is rhino tranq in Kentucky?

Medetomidine has been detected in Kentucky. University of Kentucky public health materials report its identification in the illicit fentanyl supply in several Kentucky counties.

Does Narcan work on medetomidine?

Naloxone does not directly reverse medetomidine because it is not an opioid. Naloxone should still be administered during a suspected opioid overdose because fentanyl may also be present and naloxone can reverse its opioid effects.

Why might someone remain unconscious after Narcan?

Fentanyl may not be the only substance involved. Naloxone can reverse opioid effects while medetomidine or another non-opioid sedative continues causing profound sedation. Call 911 whenever an overdose is suspected.

What does “dex” mean in street drugs?

“Dex” is one term associated with medetomidine. Street terminology varies considerably, so the name alone cannot reliably determine what a substance contains.

What does medetomidine withdrawal look like?

Reported symptoms include rapid heart rate, severe high blood pressure, tremors, altered alertness, chest pain, nausea and vomiting. Severe symptoms may require hospital treatment.

Is medetomidine replacing xylazine?

Medetomidine replaced xylazine as the most common adulterant in Philadelphia’s illicit opioid supply during the final four months of 2024. That does not establish that the same replacement is occurring throughout Kentucky or nationwide.

Can fentanyl contain both xylazine and medetomidine?

Yes. Illicit drug samples can contain multiple substances. Someone may therefore be exposed to fentanyl, medetomidine, xylazine or other drugs in the same product.

Can someone become dependent on medetomidine without knowing it?

Repeated exposure may lead to physical dependence. Because medetomidine can be present in illicit fentanyl, a person may repeatedly consume it without intentionally seeking the substance.

When should someone seek emergency care?

Call 911 for a suspected overdose or symptoms such as loss of consciousness, breathing problems, chest pain, seizures, extreme changes in heart rate, severe hypertension, persistent vomiting or major changes in alertness.

Getting Help for Fentanyl Addiction in Kentucky

The illicit opioid supply has changed repeatedly.

Fentanyl transformed overdose risk. Xylazine introduced another dangerous variable. Now medetomidine has emerged in communities across the country and has been detected here in Kentucky.

For people living with opioid addiction, the concern is not simply which adulterant comes next. It is that the contents of illicit fentanyl can change faster than someone using it can reasonably anticipate.

Recovery provides a way out of that uncertainty.

If you or someone you love is struggling with fentanyl, opioid addiction or polysubstance use, contact Kentucky Recovery Center to speak with the admissions team about treatment options.

The team can help review your situation, discuss insurance coverage and determine what next step may be appropriate.

If you are experiencing a suspected overdose or medical emergency, call 911.

Clinical Sources and References

This article reflects emerging public health information available as of August 2026. Because the illicit drug supply changes rapidly, local medetomidine prevalence and terminology may continue to evolve.

Centers for Disease Control and Prevention. Medetomidine Situation Summary. Updated April 2, 2026.

Centers for Disease Control and Prevention. Medetomidine in the U.S. Illegal Fentanyl Supply Increasing Risk for Overdose and Severe Withdrawal Syndrome. Health Alert Network Health Advisory, April 2, 2026.

Centers for Disease Control and Prevention. Notes from the Field: Suspected Medetomidine Withdrawal Syndrome Among Fentanyl-Exposed Patients — Philadelphia, Pennsylvania, September 2024–January 2025. MMWR, May 1, 2025.

Centers for Disease Control and Prevention. Xylazine: What You Should Know.

University of Kentucky College of Public Health. Know the Risks: Medetomidine.

White House Office of National Drug Control Policy. ONDCP, CDC Release Health Advisory on Medetomidine in Illicit Fentanyl. April 6, 2026.